| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 14.5412 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 14.5412. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 9,312 compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 40.6199 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 40.6199. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 102.9% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 23,137 compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 126.434 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 126.434. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 177,917 compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 17.1696 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 17.1696. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 464 compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.88965 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.88965. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 8,043 compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.25776 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.27013 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.27013. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 48.5% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 6,214 compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1123.7 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1123.7. The average price that 207940.KS shares were previous bought at was KRW 720.66. The current market price is 55.9% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 34,804 compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 8.24603 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 8.24603. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 57.6% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 103,596 compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.83566 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.83566. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -25.1% lower than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 13,338 compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 73.8668 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 73.8668. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 36.1% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 47,907 compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 119.334 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 119.334. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 196.9% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 44,186 compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 35.7728 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 35.7728. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 5,789 compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 94.9618 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 94.9618. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 29.7% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 35,489 compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 25.669 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 25.669. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -30.5% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 49,467 compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.67106 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.67106. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 37,406 compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 31.315 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 31.315. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 298,880 compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.7183 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.7183. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 15.1% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 4,314 compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.9299 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.9299. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 243 compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.4428 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.4428. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 5,634 compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.39295 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.39295. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 902 compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.62799 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.62799. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -46.2% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 126,533 compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 30.9567 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 30.9567. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 29,376 compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.76873 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.76873. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 4,903 compared to the previous valuation of Japan Lifeline Co., Ltd. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 28.3594 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 28.3594. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 63,470 compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.7218 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.7218. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is 13.6% higher than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 147,384 compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 11.5689 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 11.5689. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 24.3% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 123,476 compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 154.37 | USD 0 | The current share valuation price of A based on adjusted close was USD 154.37. The average price that A shares were previous bought at was USD 118.65. The current market price is 30.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 227.66 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 227.66. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 19.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.64. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 10.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 128.54 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 128.54. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 3.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 24.81 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 24.81. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 42.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 73.25 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 73.25. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 14.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 19.72 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 19.72. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 211.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.72 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.72. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is -5.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 344.57 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 344.57. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 19.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 15 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 15. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 26.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 42.16 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 42.16. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 84.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.79998 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.79998. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -58.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.42 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.42. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is 9.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 23.05 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 23.05. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is -15.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 36.03 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 36.03. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is 8.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of AtriCure Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.37 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.37. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 85.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 28.55 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 28.55. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 69.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 150.98 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 150.98. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 43.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 63.8932 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 63.8932. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 24,803 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 28.7888 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 28.7888. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 15.6% higher than average price they were purchased at. The value of the holding in BAVA.CO has fallen by DKK 34,070 compared to the previous valuation of |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.1 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.1. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -9.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 25.03 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 25.03. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 40.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.94 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.94. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 42.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 126.728 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 126.728. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 44,557 compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 327.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 327.03. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 16.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 327.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 327.03. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 16.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 32.699 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 32.699. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 40.0% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 30,864 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 26.68 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 26.68. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is -0.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of BioLife Solutions Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 49.25 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 49.25. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -9.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 17.81 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 17.81. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -8.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Caredx Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 9.14 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 9.14. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is -13.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Certara Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 44.84 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 44.84. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 35.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 121.396 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 121.396. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 65.8% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 24,129 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.43 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.43. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is 5.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CRL - Creightons Plc | HOLD | 0 @ USD 178.94 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 178.94. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 10.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 73.29 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 73.29. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -34.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of CorVel Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.94 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.94. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 104.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.6 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.6. The average price that CTKB shares were previous bought at was USD 5.75945. The current market price is -2.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Cytek Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.41 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.41. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is 27.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 15.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 15.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 71.2134 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 71.2134. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 38.2% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 23,653 compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.43 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.43. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -12.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 62.53 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 62.53. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -21.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 10.2316 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 10.2316. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 70.0% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 56,464 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.17063 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.17063. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is 11.0% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 174,523 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 12.57 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 12.57. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -17.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Embecta Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.7599 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.7599. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in EUZ.DE has increased by EUR 7,684 compared to the previous valuation of Eckert & Ziegler SE however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.2 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.2. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -60.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Evolent Health Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.74104 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.74104. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 23,786 compared to the previous valuation of Evotec SE however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.75. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 18.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.45 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.45. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 95.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 44.21 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 44.21. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 22.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 12.63 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 12.63. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is 23.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 107.79 | USD 0 | The current share valuation price of GH based on adjusted close was USD 107.79. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 151.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 127.51 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 127.51. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 24.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 30.9805 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 30.9805. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 4,819 compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 315.287 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 315.287. The average price that GMAB.CO shares were previous bought at was DKK 216.281. The current market price is 45.8% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 205,494 compared to the previous valuation of |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.8765 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.8765. The average price that GSK.L shares were previous bought at was GBP 18.6488. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 86,632 compared to the previous valuation of GlaxoSmithKline PLC |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 72.66 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 72.66. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 24.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.83976 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.83976. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 38,541 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.8 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.8. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 14.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 35.56 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 35.56. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is 9.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 13.12 | USD 0 | The current share valuation price of IART based on adjusted close was USD 13.12. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -39.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.13 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.13. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -25.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.88 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.88. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 63.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.81 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.81. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 40.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.44 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.44. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is 0.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 144.236 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 144.236. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 28,250 compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 231.8 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 231.8. The average price that IQV shares were previous bought at was USD 158. The current market price is 46.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 574.23 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 574.23. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 9.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 34.69 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 34.69. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 37.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 207.56 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 207.56. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 33.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.54 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.54. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 14.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.99 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.99. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 35.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.43 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.43. The average price that LAB shares were previous bought at was USD 1.33. The current market price is 7.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 206.16 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 206.16. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 83.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 63.84 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 63.84. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 52.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 58.75 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 58.75. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -31.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 679.044 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 679.044. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 159,626 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 105.02 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 105.02. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 22.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 606.6 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 606.6. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 81.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 86.22 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 86.22. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 17.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of LYXETFETUSITETFP however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 31.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 31.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 25.01 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 25.01. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -3.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.09. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 84.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.64. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 23.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 7.6 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 7.6. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -14.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Myriad Genetics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.58 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.58. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 22.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 6.04 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 6.04. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -43.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.4921 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.4921. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 92.4% higher than average price they were purchased at. The value of the holding in NEU.AX has fallen by AUD 3,074 compared to the previous valuation of |
| NOVN.SW - | HOLD | 0 @ CHF 129.947 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 129.947. The average price that NOVN.SW shares were previous bought at was CHF 108.348. The current market price is 19.9% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 95,014 compared to the previous valuation of |
| NTRA - Natera Inc | HOLD | 0 @ USD 237.12 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 237.12. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 48.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 8.01 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 8.01. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 139.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 6.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 6.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.76 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.76. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -45.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.84042 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.84042. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 21,585 compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.39 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.39. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 82.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.71 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.71. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 6.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.687 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.687. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 104.6% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 53,497 compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 89.5675 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 89.5675. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 5,181 compared to the previous valuation of Pharma Mar SA |
| PME.AX - | HOLD | 0 @ AUD 174.242 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 174.242. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 274,632 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 326.8 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 326.8. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 18.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 188.54 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 188.54. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 378.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 86.25 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 86.25. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 75.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 27.5 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 27.5. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -7.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Quidel Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 48.0534 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 48.0534. The average price that QIA.DE shares were previous bought at was EUR 42.3912. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 96,255 compared to the previous valuation of QIAGEN NV |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 25.56 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 25.56. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 194.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 171.18 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 171.18. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 25.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.26 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.26. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 58.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.03 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.03. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 111.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 397.889 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 397.889. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 9,443 compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 384.104 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 384.104. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 26.2% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 185,388 compared to the previous valuation of |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 104.66 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 104.66. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 19.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.41 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.41. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is -14.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 107.42 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 107.42. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 67.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 17.42 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 17.42. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -25.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 30.7371 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 30.7371. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 73,767 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 89.6616 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 89.6616. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -28.1% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 25,822 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 17.29 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 17.29. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -35.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 20.95 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 20.95. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -63.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 284.529 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 284.529. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 126,291 compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.21 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.21. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 168.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 46.26 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 46.26. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 32.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 54.749 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 54.749. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in SXS.L has increased by GBP 7,931 compared to the previous valuation of Spectris PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 64.63 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 64.63. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is 10.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 172.617 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 172.617. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -14.9% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 3,279 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 33.41 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 33.41. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -2.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 593.25 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 593.25. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 45.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 20.73 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 20.73. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -6.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Tandem Diabetes Care Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.7 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.7. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -26.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 56.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 56.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 276.529 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 276.529. The average price that UCB.BR shares were previous bought at was EUR 194.115. The current market price is 42.5% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 72,908 compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 47.71 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 47.71. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 52.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -20.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -20.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.98564 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.98564. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 74.3% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 43,590 compared to the previous valuation of Valneva SE however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 5.3 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 5.3. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is 18.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 31.72 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 31.72. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 61.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 19.7144 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 19.7144. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -53.8% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 25,437 compared to the previous valuation of however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 27.33 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 27.33. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 91.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |